[Paper Review] Colorectal cancers differ in respect of PARP-1 protein expression

Violetta Sulżyc‐Bielicka, Paweł Domagała+4 more|PubMed|Jul 25, 2012

PARP inhibition in cancer therapy26 references22 citations

TL;DR

This study investigates PARP-1 protein expression in 151 colorectal cancer (CRC) specimens using immunohistochemistry, revealing significant heterogeneity: 68.2% of CRCs show high nuclear PARP-1 expression, with markedly higher levels in colon cancers (79.1%) than rectal cancers (53.9%), and increased expression in stage B2 versus stage C tumors. These findings suggest PARP-1 expression levels may guide patient selection for PARP inhibitor therapy in CRC.

ABSTRACT

Recent findings raise the possibility of PARP inhibitor therapy in colorectal cancers (CRCs). However, the extent of PARP-1 protein expression in clinical specimens of CRC is not known. Using immunohistochemistry we assessed PARP-1 protein expression in tissue microarrays of 151 CRCs and its association with the patient's age, sex, Astler-Coller stage, grade and site of the tumor. High PARP nuclear immunoreactivity was found in 68.2% (103/151) of all cases. In turn, 31.8% (48/151) of tumors showed low PARP expression, including 9 (6%) PARP-1 negative CRCs. There was a significant association of PARP-1 expression with the site of CRC and Astler-Coller stage. A high PARP expression was noted in 79.1% of colon vs. 53.9% of rectal tumors (p = 0.001). The mean PARP-1 score was 1.27 times higher in colon vs. rectal cancers (p = 0.009) and it was higher in stage B2 vs. stage C of CRCs (p = 0.018). In conclusion, the level of PARP-1 protein nuclear expression is associated with the tumor site and heterogeneous across clinical specimens of CRC, with the majority of CRCs expressing a high level but minority - low or no PARP-1 expression. These findings may have a clinical significance because the assessment of PARP-1 expression in tumor samples may improve selection of patients with CRC for PARP inhibitor therapy.

Motivation & Objective

• To assess the extent and distribution of PARP-1 protein expression in clinical specimens of colorectal cancer (CRC).
• To investigate associations between PARP-1 expression levels and clinical parameters such as tumor site, stage, grade, age, and sex.
• To evaluate the potential of PARP-1 expression as a predictive biomarker for PARP inhibitor therapy in CRC.

Proposed method

• Immunohistochemistry was performed on tissue microarrays containing 151 CRC specimens to detect nuclear PARP-1 protein expression.
• PARP-1 expression was scored and categorized as high, low, or negative based on immunoreactivity intensity and distribution.
• Statistical analysis was used to assess associations between PARP-1 expression levels and clinical variables including Astler-Coller stage, tumor site, grade, age, and sex.
• The study compared PARP-1 expression levels between colon and rectal cancers and across different stages of CRC.

Experimental results

Research questions

• RQ1 What is the prevalence of high versus low PARP-1 protein expression in a cohort of 151 colorectal cancer specimens?
• RQ2 Is there a significant association between PARP-1 expression levels and the anatomical site of colorectal tumors (colon vs. rectum)?
• RQ3 Does PARP-1 expression vary according to Astler-Coller stage of colorectal cancer?
• RQ4 Is PARP-1 expression correlated with patient age, sex, or tumor grade in CRC?
• RQ5 Can PARP-1 expression levels serve as a predictive biomarker for response to PARP inhibitor therapy in CRC?

Key findings

• High PARP-1 nuclear immunoreactivity was observed in 68.2% (103/151) of colorectal cancer cases.
• Low PARP-1 expression was found in 31.8% (48/151) of cases, including 9 (6%) PARP-1 negative tumors.
• Colon cancers exhibited significantly higher PARP-1 expression than rectal cancers, with 79.1% of colon tumors showing high expression versus 53.9% of rectal tumors (p = 0.001).
• The mean PARP-1 score was 1.27 times higher in colon cancers compared to rectal cancers (p = 0.009).
• PARP-1 expression was significantly higher in stage B2 compared to stage C colorectal cancers (p = 0.018).
• A significant association was found between PARP-1 expression and both tumor site and Astler-Coller stage, indicating heterogeneity across CRC specimens.